SAB Biotherapeutics (SABS) Payables (2020 - 2026)

SAB Biotherapeutics' Payables history runs 7 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• Quarterly Payables rose 33.32% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 33.32% YoY) and the FY2025 annual result came in at $3.1 million, up 59.64% from the prior year.
• Payables was $3.5 million for Q1 2026 at SAB Biotherapeutics, up from $3.1 million in the prior quarter.
• Across five years, Payables topped out at $6.0 million in Q1 2022 and bottomed at $1.3 million in Q3 2024.
• A 5-year average of $3.0 million and a median of $2.6 million in 2025 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables plunged 70.97% — and 2025, when it jumped 127.83%.
• SAB Biotherapeutics' Payables stood at $4.5 million in 2022, then slumped by 55.15% to $2.0 million in 2023, then dropped by 1.31% to $2.0 million in 2024, then jumped by 59.64% to $3.1 million in 2025, then climbed by 12.69% to $3.5 million in 2026.
• Business Quant data shows SABS's Payables at $3.5 million in Q1 2026, $3.1 million in Q4 2025, and $3.0 million in Q3 2025.